CN102302453A - Paroxetine hydrochloride liposome solid preparation - Google Patents
Paroxetine hydrochloride liposome solid preparation Download PDFInfo
- Publication number
- CN102302453A CN102302453A CN 201110271970 CN201110271970A CN102302453A CN 102302453 A CN102302453 A CN 102302453A CN 201110271970 CN201110271970 CN 201110271970 CN 201110271970 A CN201110271970 A CN 201110271970A CN 102302453 A CN102302453 A CN 102302453A
- Authority
- CN
- China
- Prior art keywords
- paroxetine hydrochloride
- liposome
- solid preparation
- preparation
- hydrogenated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- AHOUBRCZNHFOSL-UHFFFAOYSA-N 3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine Chemical compound C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 title claims abstract description 354
- 229960005183 paroxetine hydrochloride Drugs 0.000 title claims abstract description 170
- 239000002502 liposome Substances 0.000 title claims abstract description 140
- 238000002360 preparation method Methods 0.000 title claims abstract description 85
- 239000007787 solid Substances 0.000 title claims abstract description 53
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 76
- 239000000203 mixture Substances 0.000 claims abstract description 53
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 38
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 claims abstract description 20
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 41
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 39
- 235000010445 lecithin Nutrition 0.000 claims description 39
- 239000000787 lecithin Substances 0.000 claims description 39
- 229940067606 lecithin Drugs 0.000 claims description 39
- 210000002969 egg yolk Anatomy 0.000 claims description 37
- 235000010469 Glycine max Nutrition 0.000 claims description 36
- 244000068988 Glycine max Species 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 30
- 239000000243 solution Substances 0.000 claims description 29
- 239000000843 powder Substances 0.000 claims description 27
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 21
- 229920001219 Polysorbate 40 Polymers 0.000 claims description 19
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 claims description 19
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 claims description 19
- 229940101027 polysorbate 40 Drugs 0.000 claims description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 239000007853 buffer solution Substances 0.000 claims description 16
- 239000003960 organic solvent Substances 0.000 claims description 16
- 239000008187 granular material Substances 0.000 claims description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 12
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 230000006837 decompression Effects 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 230000036571 hydration Effects 0.000 claims description 9
- 238000006703 hydration reaction Methods 0.000 claims description 9
- 239000012982 microporous membrane Substances 0.000 claims description 9
- 238000001694 spray drying Methods 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- 229910019142 PO4 Inorganic materials 0.000 claims description 8
- 239000008366 buffered solution Substances 0.000 claims description 8
- 239000010452 phosphate Substances 0.000 claims description 8
- 239000011230 binding agent Substances 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 7
- 239000012046 mixed solvent Substances 0.000 claims description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 7
- 239000000080 wetting agent Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 239000007779 soft material Substances 0.000 claims description 6
- 239000008363 phosphate buffer Substances 0.000 claims description 5
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 4
- 239000008351 acetate buffer Substances 0.000 claims description 4
- 239000000337 buffer salt Substances 0.000 claims description 4
- 239000007979 citrate buffer Substances 0.000 claims description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 4
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 2
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 28
- 230000000694 effects Effects 0.000 abstract description 19
- 238000004090 dissolution Methods 0.000 abstract description 10
- 231100000331 toxic Toxicity 0.000 abstract description 6
- 230000002588 toxic effect Effects 0.000 abstract description 6
- 239000008347 soybean phospholipid Substances 0.000 abstract description 3
- 230000005923 long-lasting effect Effects 0.000 abstract 1
- 229920000136 polysorbate Polymers 0.000 abstract 1
- 239000002245 particle Substances 0.000 description 26
- 230000000052 comparative effect Effects 0.000 description 14
- 229960002296 paroxetine Drugs 0.000 description 14
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 13
- 238000009826 distribution Methods 0.000 description 11
- 229940079593 drug Drugs 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000012528 membrane Substances 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 7
- 150000003904 phospholipids Chemical class 0.000 description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000000314 lubricant Substances 0.000 description 6
- 238000005325 percolation Methods 0.000 description 6
- 239000000600 sorbitol Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000001856 Ethyl cellulose Substances 0.000 description 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 5
- 229920000881 Modified starch Polymers 0.000 description 5
- 230000001476 alcoholic effect Effects 0.000 description 5
- -1 cholic acid derivative salts Chemical class 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 5
- 235000019325 ethyl cellulose Nutrition 0.000 description 5
- 229920001249 ethyl cellulose Polymers 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- CSVGEMRSDNSWRF-UHFFFAOYSA-L disodium;dihydrogen phosphate Chemical compound [Na+].[Na+].OP(O)([O-])=O.OP(O)([O-])=O CSVGEMRSDNSWRF-UHFFFAOYSA-L 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229940042880 natural phospholipid Drugs 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229940023488 pill Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 210000002706 plastid Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- DSNRWDQKZIEDDB-SQYFZQSCSA-N 1,2-dioleoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-SQYFZQSCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000019890 Amylum Nutrition 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 244000147568 Laurus nobilis Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010029897 Obsessive thoughts Diseases 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920002593 Polyethylene Glycol 800 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 239000002812 cholic acid derivative Substances 0.000 description 1
- 125000003716 cholic acid group Chemical group 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 229940026529 paroxetine oral tablet Drugs 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- SPOMEWBVWWDQBC-UHFFFAOYSA-K tripotassium;dihydrogen phosphate;hydrogen phosphate Chemical compound [K+].[K+].[K+].OP(O)([O-])=O.OP([O-])([O-])=O SPOMEWBVWWDQBC-UHFFFAOYSA-K 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses a paroxetine hydrochloride liposome solid preparation and a preparation method thereof. According to the invention, an active component paroxetine hydrochloride and a specific composition of hydrogenated ovolecithin, cholesterol, hydrogenated soybean phospholipids, tween 40 and PEG600 are prepared into a liposome. Therefore, the dissolution rate, the stability and the bioavailability of the medicine are greatly improved. The effect of the medicine is released smoothly, and the effect is long-lasting. The curative effect of the medicine is substantial. With the preparation, the quality of the preparation product is improved, and toxic and side-effects are reduced.
Description
Technical field
The present invention relates to a kind of lipidosome solid preparation, be specifically related to paroxetine hydrochloride lipidosome solid preparation and method for making thereof, belong to the pharmaceutical preparations technology field.
Background technology
Paroxetine hydrochloride is white or off-white color crystalline powder, and odorless, bitter in the mouth are soluble in methanol; In ethanol, dissolve, slightly soluble in water, its chemical name is: (-)-anti--4-(4-fluorophenyl)-3-{[3; 4-(methylenedioxy group) phenoxy group] methyl }-piperidine hydrochlorate, molecular formula: C
19H
20NO
3FHCl, molecular weight: 365.84, structural formula is:
Paroxetine hydrochloride is developed by the U.S., and it is a selectivity nervus centralis serotonin reuptake inhibitor, can make that 5-hydroxy tryptamine concentration increases in the synaptic space, the performance antidepressant effect.A little less than other mediator effect, less to the unify influence of cardiovascular system of autonomic nerve system.
The oral easy absorption of paroxetine hydrochloride is not subjected to the influence of antiacid medicine or food, oral 30mg, and reaching the peak concentration time is 6.3h, and peak concentration is 17.6ug/ml, and T1/2 is 24h, and apparent branch is long-pending to be 3-28L/kg.Plasma protein binding rate is 95%.7-14 reaches Cpss in day, and is distributed to each histoorgan rapidly, and at liver metabolism, about 2% with original shape discharge from urine, and all the other are then discharged from urine with the metabolite form, and fraction is from defecate.Clinically be used to treat depression.Also can treat obsession, panic disorder or social anxiety disorder.
The marketed drug preparation that with the paroxetine hydrochloride is active constituents of medicine now is mainly tablet.The paroxetine hydrochloride disintegration of tablet time is long, and dissolution and dissolution rate are low, absorption difference, and bioavailability is low, has influenced the performance of paroxetine hydrochloride clinical treatment effect.
WO9520964A discloses a kind of combination of oral medication that contains paroxetine resin coordination compound, to shelter the bitterness of paroxetine.WO9703670A discloses a kind of paroxetine controlled release compositions, to reduce the side effect of paroxetine oral tablet.WO9926625A discloses the paroxetine preparation of solubilising, to improve its dissolubility.Only if WO9520964A discloses paroxetine in waterless operation, otherwise can the pulverize redness.CN1568987A discloses a kind of paroxetine hydrochloride drop pill, though pill occurred, the bioavailability each side is improved, and with respect to our the present lipidosome solid preparation of doing, its long-time stability and toxic and side effects all have much room for improvement.CN1853631A discloses the fast disintegrant of the paroxetine that contains the coating taste masking.WO2006033505A discloses the paroxetine cholate of paroxetine derivatization or cholic acid derivative salts and has comprised paroxetine and the compositions of cholic acid or chlolic acid derivatives.CN101143136A discloses a kind of paroxetine slow release micropills preparation; It is characterized in that: described preparation contains polymeric slow releasing composition; Comprise: the label that contains the paroxetine of treatment effective dose and/or preventive dose; And the micropill that is applied to said label; It partly covers the surface of this label, slowly dissolving in liquid, aqueous.CN101371836A discloses a kind of gentle slow release compositions of time-delay that contains paroxetine or its salt that pharmaceutically is suitable for, and it is characterized in that said composition is a kind of at the oral enteric sustained-release composition that slowly discharges through quilt behind the stomach.More than these preparations still have various deficiencies.
The main mechanism of action of liposome is drug powder or solution are wrapped in the aqueous phase that the liposome bilayer lipid membrane sealed or embed in the liposome bilayer lipid membrane; This microgranule has a type cellularity; Get into the interior back of human body and activated the autoimmune function of body by reticuloendothelial system phagocytic; Distributed in the body of entrapped drug thereby change; Drug main will be put aside in histoorgans such as spleen, liver, lung and bone marrow; Thereby improve the therapeutic index of medicine, reduce the therapeutic dose and the toxicity that reduces medicine of medicine.
If paroxetine hydrochloride can be processed liposome; Then be expected to overcome a series of problems that existing paroxetine hydrochloride preparation exists; Improve the dissolubility and the stability of medicine; Prolong drug retention time in vivo; Improve bioavailability; Improve the formulation products quality, reduced toxic and side effects, improved treatment speed and therapeutic effect.
But the preparation liposome need be selected suitable liposome constituent and method for making, and this need carry out a large amount of experiment sievings and have certain degree of difficulty.Because the character of liposome is directly closely related with the composition of liposome like stability, envelop rate, onset time, in vivo circulation time, bioavailability and toxic and side effects etc.; And the composition of liposome is directly closely related with the character of the entrapped drug of wanting; So selecting which type of composition to form the paroxetine hydrochloride liposome with better quality is the problem that needs to be resolved hurrily.
We are through a large amount of research experiments; Be surprisingly found out that; The lipidosome solid preparation that adopts particular excipient and paroxetine hydrochloride to process; Can further improve the stability of principal agent effectively; Improve the dissolution of medicine simultaneously; Delay the release of medicine, increase medicine retention time in vivo.
Summary of the invention
The inventor is through discover in a large number; Through paroxetine hydrochloride, hydrogenated yolk lecithin, cholesterol, hydrogenated soya phosphatide, polysorbate40 and the PEG600 that selects the specified weight proportioning for use; Can form the paroxetine hydrochloride liposome of excellent quality; Again liposome is processed solid preparation with general formulation method, thereby accomplish the present invention.
The purpose of this invention is to provide a kind of paroxetine hydrochloride liposome, it is processed by the supplementary material composition that comprises following weight proportion:
Condition is: hydrogenated yolk lecithin: cholesterol: the weight ratio of hydrogenated soya phosphatide is 3～4: 1: 2～3; Hydrogenated yolk lecithin preferably: cholesterol: the weight ratio of hydrogenated soya phosphatide is 3: 1: 2.
Another object of the present invention provides the method for preparing of above-mentioned paroxetine hydrochloride liposome, and this method may further comprise the steps:
(a) paroxetine hydrochloride, hydrogenated yolk lecithin, cholesterol, hydrogenated soya phosphatide, polysorbate40 and PEG600 are dissolved in the organic solvent, stir and make its dissolving;
(b) above-mentioned solution is placed eggplant-shape bottle, organic solvent is removed in 46 ℃ of water-bath decompressions, on the bottle wall, forms uniformly transparent film;
(c) in eggplant-shape bottle, add buffer solution, continue to make the films swell hydration 46 ℃ of water-bath normal pressure rotations;
(d) with above-mentioned solution with 0.45 μ m filtering with microporous membrane, filtrating is placed-20 ℃ of refrigerator and cooled freeze and spends the night, take out to melt then, multigelation three times, spray drying makes paroxetine hydrochloride liposome powder.
A further object of the present invention provides a kind of paroxetine hydrochloride lipidosome solid preparation, and it is processed by paroxetine hydrochloride liposome (intermediate products) and other pharmaceutic adjuvants,
Wherein said paroxetine hydrochloride liposome is processed by the supplementary material composition that comprises following weight proportion:
Condition is: based on the paroxetine hydrochloride of a weight ratio, hydrogenated yolk lecithin: cholesterol: the weight ratio of hydrogenated soya phosphatide is 3～4: 1: 2～3; Hydrogenated yolk lecithin preferably: cholesterol: the weight ratio of hydrogenated soya phosphatide is 3: 1: 2.
Preferably, paroxetine hydrochloride: hydrogenated yolk lecithin: cholesterol: the weight ratio of hydrogenated soya phosphatide is 1: 3: 1: 2.
Preferably, wherein said paroxetine hydrochloride liposome is processed by the supplementary material composition that comprises following weight proportion:
Based on the paroxetine hydrochloride of 1 weight portion, the amount of other pharmaceutic adjuvants is the 1-3.5 weight portion.
A further object of the present invention provides the method for preparing of above-mentioned paroxetine hydrochloride lipidosome solid preparation, and this method may further comprise the steps:
(1) preparation of paroxetine hydrochloride liposome: paroxetine hydrochloride, hydrogenated yolk lecithin, cholesterol, hydrogenated soya phosphatide, polysorbate40 and PEG600 are prepared into the liposome powder together;
(2) preparation of paroxetine hydrochloride lipidosome solid preparation: liposome powder and other pharmaceutic adjuvants are mixed with the paroxetine hydrochloride lipidosome solid preparation.
Wherein, said pharmaceutic adjuvant is selected from diluent, disintegrating agent, binding agent, wetting agent, lubricant and combination thereof.
Wherein, the preparation of step (1) paroxetine hydrochloride plastid preferably includes following substep:
(a) paroxetine hydrochloride, hydrogenated yolk lecithin, cholesterol, hydrogenated soya phosphatide, polysorbate40 and PEG600 are dissolved in the organic solvent, stir and make its dissolving;
(b) above-mentioned solution is placed eggplant-shape bottle, organic solvent is removed in 46 ℃ of water-bath decompressions, on the bottle wall, forms uniformly transparent film;
(c) in eggplant-shape bottle, add buffer solution, continue to make the films swell hydration 46 ℃ of water-bath normal pressure rotations;
(d) with above-mentioned solution with 0.45 μ m filtering with microporous membrane, filtrating is placed-20 ℃ of refrigerator and cooled freeze and spends the night, take out to melt then, multigelation three times, spray drying makes paroxetine hydrochloride liposome powder.
The preparation of step (2) paroxetine hydrochloride liposome solid preparation preferably includes following substep:
(e) paroxetine hydrochloride liposome powder and diluent, disintegrating agent and binding agent are mixed, the mix homogeneously that sieves adds wetting agent and prepares soft material, the preparation that sieves, drying;
(f) dried granule and mix lubricant is even, granulate sieves;
(g) tabletting makes the paroxetine hydrochloride lipidosome solid preparation.
Compare with existing ordinary preparation, paroxetine hydrochloride lipidosome solid preparation provided by the invention has improved preparation dissolution, stability and bioavailability greatly; Reduce toxic and side effects, improved the formulation products quality, improved therapeutic effect, improved clinical safety in utilization.
Description of drawings
Fig. 1 is the release in vitro curve of listing Comparative formulation and embodiment 1-3 sample, and wherein trunnion axis is represented 0～24 hour time, and vertical axis is represented the cumulative release percent of paroxetine hydrochloride.Wherein, the release profiles of curve 1 expression listing Comparative formulation, the release profiles of curve 2 expression embodiment 1 sample, the release profiles of curve 3 expression embodiment 2 samples, the release profiles of curve 4 expression embodiment 3 samples.
The specific embodiment
Through the specific embodiment the present invention is further specified, characteristics of the present invention and advantage more clearly are described.
In order to obtain colory paroxetine hydrochloride lipidosome solid preparation; Thereby important is to seek good compatible with paroxetine hydrochloride it well to be sealed and non-leakage material; Be convenient to form colory paroxetine hydrochloride liposome; Make that the stripping property excellence and the bioavailability of this liposome are high, and seek the relative best pharmaceutic adjuvant that can form solid preparation with the paroxetine hydrochloride liposome.
To achieve these goals; Big quantity research and test that the inventor carries out; The paroxetine hydrochloride liposome that paroxetine hydrochloride, hydrogenated yolk lecithin, cholesterol, hydrogenated soya phosphatide, polysorbate40 and the PEG600 of discovery specified weight proportioning can process; Wherein, Paroxetine hydrochloride envelop rate as active constituents of medicine is high, and stripping property is good, and the retention time of the active constituents of medicine in the gained solid preparation in the body circulation is long; Bioavailability is high, and curative effect is high.
On the one hand, the present invention provides a kind of paroxetine hydrochloride liposome, and it is processed by the supplementary material composition that comprises following weight proportion:
Condition is: hydrogenated yolk lecithin: cholesterol: the weight ratio of hydrogenated soya phosphatide is 3～4: 1: 2～3; Hydrogenated yolk lecithin preferably: cholesterol: the weight ratio of hydrogenated soya phosphatide is 3: 1: 2.
Preferably, paroxetine hydrochloride liposome provided by the invention is processed by the supplementary material composition that comprises following weight proportion:
As the phospholipid that is used to form liposome, it is of a great variety, and commonly used have natural phospholipid and a synthetic phospholipid.Natural phospholipid comprises Ovum Gallus domesticus Flavus lecithin, Phosphatidylserine, PHOSPHATIDYL ETHANOLAMINE, lecithin, hydrogenation egg yolk lecithin, EPG, egg yolk lecithin acyl serine, egg yolk lecithin acyl inositol, soybean lecithin, hydrogenated soya phosphatide, soybean phospholipid acyl glycerol, soy phosphatidylserine and soybean phospholipid acyl inositol etc.Synthetic phospholipid comprises dioleoyl phospholipid phatidylcholine, distearyl acid phosphatidylcholine, dipalmitoyl phosphatidyl choline, two myristoyl phosphatidylcholines, two Laurel phosphatidyl cholines, DOPG, distearyl phosphatidyl glycerol, two palmityl phosphatidyl glycerols, GLYCEROL,DIMYRISTOYL PHOSPHATIDYL, two lauroyl phosphatidyl glycerols etc.
The inventor is through long term studies; Through a large amount of screening tests; Find to adopt paroxetine hydrochloride liposome that single phospholipid commonly used and additives prepare for the film material under the accelerated test of 40 ℃ of high temperature, relative humidity 75% ± 5%; Stability and envelop rate are not good, and percolation ratio is up to more than 30%.
Research shows that the stability of liposome and stripping property and bioavailability have close corresponding relation.Stability is high more, and stripping property is good more, and bioavailability is high more.Therefore, the stability of paroxetine hydrochloride liposome of the present invention is high, stripping property is excellent, is to cause one of high factor of drug bioavailability.
The inventor is through conscientiously discover the hydrogenated yolk lecithin of appropriate amount: cholesterol for a long time: hydrogenated soya phosphatide is with weight ratio 3～4: the film materials of 1: 2～3 combinations can be used to form colory paroxetine hydrochloride liposome.Can form suitably size, well-balanced through the method that provides among the present invention; The liposome that the envelop rate of appropriate configuration composition is high; And these compositions, especially paroxetine hydrochloride are non-leakage in formed liposome, and the stripping property of paroxetine hydrochloride is excellent in the liposome.If use consumption to be hydrogenated yolk lecithin: cholesterol: hydrogenated soya phosphatide weight ratio 3～4: the scope beyond 1: 2～3; Perhaps select other phospholipid material such as Phosphatidylserine etc. for use; Then the poor stability of formed liposome, envelop rate is low, stripping property is poor, can not realize the object of the invention.
In paroxetine hydrochloride liposome of the present invention; For the paroxetine hydrochloride of 1 weight portion; The consumption of hydrogenated yolk lecithin is the 0.75-3 weight portion, and the consumption of cholesterol is the 0.25-1 weight portion, and the weight ratio of hydrogenated yolk lecithin and cholesterol is 3～4: 1.If the consumption of hydrogenated yolk lecithin and cholesterol is lower than 0.75 weight portion and 0.25 weight portion respectively, have a large amount of free paroxetine hydrochlorides and do not sealed, the drug loading of liposome is low, and stability also can descend, and stripping property also can affect adversely; Otherwise the consumption of hydrogenated yolk lecithin and cholesterol is higher than 3 weight portions and 1 weight portion respectively, and then the envelop rate as the paroxetine hydrochloride of active constituents of medicine also can descend.
Hydrogenated soya phosphatide stability is fine, combines with hydrogenated yolk lecithin and cholesterol, can stop the cohesion of crystal structure.Hydrogenated soya phosphatide mixes the duplicature of hydrogenated yolk lecithin and cholesterol formation, is similar to " buffer agent " and equally plays the effect of regulating membrane structure " flowability ", and liposome stability is significantly strengthened.
The inventor is through discovering, when hydrogenated yolk lecithin: cholesterol: the weight ratio of hydrogenated soya phosphatide is 3～4: in the time of 1: 2～3, can form stable paroxetine hydrochloride liposome.When the weight ratio of hydrogenated soya phosphatide less than 2 the time, membrane stability reduces; When the weight ratio of hydrogenated soya phosphatide greater than 3 the time, liposome membrane is mobile uncomfortable, is wrapped in the intravital paroxetine hydrochloride of lipid and is easy to seepage.
In paroxetine hydrochloride liposome of the present invention, PEG600 and polysorbate40 are used to regulate the membrane stability and the permeability of liposome.
In paroxetine hydrochloride liposome of the present invention, use polysorbate40 further to improve the stability and the envelop rate of liposome membrane.Polysorbate40 is a kind of non-ionic surface active agent, when being used for the duplicature of hydrogenated yolk lecithin and cholesterol combination phospholipid formation, can not only further improving the dissolubility of paroxetine hydrochloride, thereby improve envelop rate; And can improve the chemical energy between this duplicature, thus the chemical stability of liposome in waterborne liquid improved, and then improve the stability of paroxetine hydrochloride liposome.
In paroxetine hydrochloride liposome of the present invention, for the paroxetine hydrochloride of 1 weight portion, the consumption of polysorbate40 is the 0.6-1 weight portion.If the consumption of polysorbate40 is lower than 0.6 weight portion; Then cause improving not enough to the stability and the envelop rate of liposome owing to its consumption is low excessively; Otherwise if the consumption of polysorbate40 is higher than 1 weight portion, it is too high and cause liposome membrane to be easy to destroy and reveal active component then to be used for its consumption.
Bound by theory not; The inventor is surprisingly found out that; Adding PEG600 can change the pharmaceutical properties of paroxetine hydrochloride liposome; Macrogol 600 has certain viscosity and surface activity effect; Can reduce the surface tension between liposome and the gastrointestinal tract mucus; Promote medicine to get into gastrointestinal mucosa, thereby improve bioavailability and therapeutic effect.After deliberation, the inventor finds that PEG600 is better than other Polyethylene Glycol such as PEG400 or PEG800.In paroxetine hydrochloride liposome of the present invention; For the paroxetine hydrochloride of 1 weight portion; The consumption of PEG600 is 0.75-2 part, and consumption is crossed and low then stability, envelop rate and the release of liposome improved inadequately, and its consumption is too high also to can not get the good liposome of expecting.
In paroxetine hydrochloride liposome of the present invention; Polysorbate40 and PEG600 through an amount of proportioning have collaborative regulating action to the immobilized artificial membrane structure that hydrogenated yolk lecithin, cholesterol, hydrogenated soya phosphatide make up; Can form envelop rate height, stable high paroxetine hydrochloride liposome; Its stripping property is excellent; Had good sustained release effect, bioavailability is high.
On the other hand, the present invention provides the method for preparing of paroxetine hydrochloride liposome, and this method may further comprise the steps:
(a) paroxetine hydrochloride, hydrogenated yolk lecithin, cholesterol, hydrogenated soya phosphatide, polysorbate40 and PEG600 are dissolved in the organic solvent, stir and make its dissolving;
(b) above-mentioned solution is placed eggplant-shape bottle, organic solvent is removed in 46 ℃ of water-bath decompressions, on the bottle wall, forms uniformly transparent film;
(c) in eggplant-shape bottle, add buffer solution, continue to make the films swell hydration 46 ℃ of water-bath normal pressure rotations;
(d) with above-mentioned solution with 0.45 μ m filtering with microporous membrane, filtrating is placed-20 ℃ of refrigerator and cooled freeze and spends the night, take out to melt then, multigelation three times, spray drying makes paroxetine hydrochloride liposome powder.
In an embodiment preferred of paroxetine hydrochloride method for preparing lipidosome of the present invention; Organic solvent described in the step (a) is selected from one or more in ethanol, chloroform, dichloromethane, methanol, n-butyl alcohol, isopropyl alcohol, acetone, benzyl alcohol, the tert-butyl alcohol, the normal hexane, preferred volume ratio be 3: 1 for ethanol and isopropyl alcohol mixed solvent.
In an embodiment preferred of paroxetine hydrochloride method for preparing lipidosome of the present invention; Buffer salt solution described in the step (c) is selected from a kind of in phosphate buffer, citrate buffer, acetate buffer, borate buffer solution and the carbonate buffer solution, and preferred pH value is 7.0 phosphate buffered solution.For example phosphoric acid-sodium hydrogen phosphate buffer, potassium dihydrogen phosphate-dipotassium hydrogen phosphate, sodium dihydrogen phosphate-sodium hydrogen phosphate, acetic acid-sodium acetate buffer solution, citric acid-sodium citrate buffer solution preferably are 7.0 phosphate buffered solution like the pH value of pharmacopeia record.
Through said method, can prepare the little and uniform paroxetine hydrochloride liposome of particle size distribution of granule, its envelop rate is high, and stability is high, and stripping property is good, and bioavailability is high.
Discover that the size of liposome is to influence the liposome principal element with the time of staying that distributes in vivo, the particle diameter of liposome is more little, and the time of staying is long more in the body.Paroxetine hydrochloride liposome particles through the inventive method preparation is little, and particle size distribution is even, and this is one of its factor that metabolic rate is low in vivo, bioavailability is high.
On the one hand, the present invention provides the paroxetine hydrochloride lipidosome solid preparation again, and it is processed by paroxetine hydrochloride liposome and other pharmaceutic adjuvants, and wherein said paroxetine hydrochloride liposome is processed by the supplementary material composition that comprises following weight proportion:
Condition is: hydrogenated yolk lecithin: cholesterol: the weight ratio of hydrogenated soya phosphatide is 3～4: 1: 2～3; Hydrogenated yolk lecithin preferably: cholesterol: the weight ratio of hydrogenated soya phosphatide is 3: 1: 2.
In an embodiment preferred of paroxetine hydrochloride lipidosome solid preparation of the present invention, the paroxetine hydrochloride liposome is processed by the supplementary material composition that comprises following weight proportion:
Based on the paroxetine hydrochloride of 1 weight portion, the amount of other pharmaceutic adjuvants is the 1-3.5 weight portion.
In this article; The meaning of used term " other pharmaceutic adjuvants " or " pharmaceutic adjuvant " and excipient equivalent in meaning; Be meant the pharmaceutic adjuvant except the paroxetine hydrochloride liposome that uses in order to prepare the paroxetine hydrochloride lipidosome solid preparation, comprise diluent, disintegrating agent, binding agent, wetting agent, lubricant and combination thereof.
In this article, used term " amounts of other pharmaceutic adjuvants " is meant the weight sum of above-mentioned pharmaceutic adjuvant.
The consumption of various pharmaceutic adjuvants can be selected according to the general consumption of each adjuvant in solid preparation by those skilled in the art, and this is in those skilled in the art's limit of power.
In an embodiment preferred of paroxetine hydrochloride lipidosome solid preparation of the present invention; Said diluent is selected from one or more in starch, lactose, sorbitol, amylum pregelatinisatum, sorbitol, microcrystalline Cellulose, the pregelatinized Starch, is preferably pregelatinized Starch, sorbitol.
In an embodiment preferred of paroxetine hydrochloride lipidosome solid preparation of the present invention; Said disintegrating agent is selected from one or more in low-substituted hydroxypropyl cellulose, carboxymethyl starch sodium, cross-linking sodium carboxymethyl cellulose, the polyvinylpolypyrrolidone, preferred low-substituted hydroxypropyl cellulose.
In an embodiment preferred of paroxetine hydrochloride lipidosome solid preparation of the present invention; Said binding agent is selected from a kind of in 30 POVIDONE K 30 BP/USP 30, starch slurry, hypromellose, sodium carboxymethyl cellulose, ethyl cellulose, arabic gum, the xanthan gum, is preferably ethyl cellulose.
In an embodiment preferred of paroxetine hydrochloride lipidosome solid preparation of the present invention, said wetting agent is the alcoholic solution of 10-80%, preferred 30% alcoholic solution.
In an embodiment preferred of paroxetine hydrochloride lipidosome solid preparation of the present invention, said lubricant is selected from one or more in magnesium stearate, zinc stearate, Pulvis Talci, micropowder silica gel, Macrogol 4000, the stearic acid, is preferably Pulvis Talci.
Paroxetine hydrochloride lipidosome solid preparation provided by the invention is a tablet.
On the one hand, the present invention provides the method for preparing of above-mentioned paroxetine hydrochloride lipidosome solid preparation again, and this method may further comprise the steps:
(1) preparation of paroxetine hydrochloride liposome: paroxetine hydrochloride, hydrogenated yolk lecithin, cholesterol, hydrogenated soya phosphatide, polysorbate40 and PEG600 are prepared into the liposome powder together;
(2) preparation of paroxetine hydrochloride lipidosome solid preparation: liposome powder and other pharmaceutic adjuvants are mixed with the paroxetine hydrochloride lipidosome solid preparation.
Wherein, said pharmaceutic adjuvant is selected from diluent, disintegrating agent, binding agent, wetting agent, lubricant and combination thereof.
In the preferred implementation of the method for preparing of paroxetine hydrochloride liposome solid preparation, the preparation of step (1) paroxetine hydrochloride plastid comprises following substep:
(a) paroxetine hydrochloride, hydrogenated yolk lecithin, cholesterol, hydrogenated soya phosphatide, polysorbate40 and PEG600 are dissolved in the organic solvent, stir and make its dissolving;
(b) above-mentioned solution is placed eggplant-shape bottle, organic solvent is removed in 46 ℃ of water-bath decompressions, on the bottle wall, forms uniformly transparent film;
(c) in eggplant-shape bottle, add buffer solution, continue to make the films swell hydration 46 ℃ of water-bath normal pressure rotations;
(d) with above-mentioned solution with 0.45 μ m filtering with microporous membrane, filtrating is placed-20 ℃ of refrigerator and cooled freeze and spends the night, take out to melt then, multigelation three times, spray drying makes paroxetine hydrochloride liposome powder.
In paroxetine hydrochloride lipidosome solid preparation method for preparing of the present invention; Organic solvent described in the substep (a) is selected from one or more in ethanol, chloroform, dichloromethane, methanol, n-butyl alcohol, isopropyl alcohol, acetone, benzyl alcohol, the tert-butyl alcohol, the normal hexane, and preferred volume ratio is 3: 1 ethanol and an isopropyl alcohol mixed solvent.
In paroxetine hydrochloride lipidosome solid preparation method for preparing of the present invention; Buffer salt solution described in the substep (c) is selected from a kind of in phosphate buffer, citrate buffer, acetate buffer, borate buffer solution and the carbonate buffer solution, and preferred pH value is 7.0 the phosphate buffered solution like the pharmacopeia record.
In an embodiment preferred of paroxetine hydrochloride lipidosome solid preparation method for preparing of the present invention, the preparation of step (2) paroxetine hydrochloride lipidosome solid preparation comprises following substep:
(e) paroxetine hydrochloride liposome powder and diluent, disintegrating agent and binding agent are mixed, the mix homogeneously that sieves adds wetting agent and prepares soft material, the preparation that sieves, drying;
(f) dried granule and mix lubricant is even, granulate sieves;
(g) tabletting makes the paroxetine hydrochloride lipidosome solid preparation.
The present invention becomes liposome through the active ingredient hydrochloric acid paroxetine with the combined preparation of the specified weight of hydrogenated yolk lecithin, cholesterol, hydrogenated soya phosphatide, polysorbate40 earlier, is mixed and made into solid preparation with other pharmaceutic adjuvant again.Gained solid preparation product quality is high, and particle diameter is even, and stability is high, and envelop rate is high, and stripping property is good, and medicine retention time in blood circulation is long, and is evident in efficacy, reduced toxic and side effects.
The method for preparing of paroxetine hydrochloride lipidosome solid preparation provided by the invention has improved product quality, and equipment is simple, processing ease, and method is simple, is suitable for industrialized great production.
With hereinafter, if explanation especially, content or consumption are all by weight.
Embodiment
Below through concrete preferred embodiment the present invention is further specified.These embodiment only are illustrative, and should not be construed as limitation of the present invention.
Embodiment 1 paroxetine hydrochloride liposome sheet
Used supplementary material is following:
Adopt following production technology to prepare paroxetine hydrochloride liposome sheet:
(1) accurately take by weighing 20g paroxetine hydrochloride, 30g hydrogenated yolk lecithin, 10g cholesterol, 20g hydrogenated soya phosphatide, 16g polysorbate40,24g PEG600, adding 400ml volume ratio is 3: 1 ethanol and an isopropyl alcohol mixed solvent, stirs and makes its dissolving;
(2) above-mentioned solution is placed eggplant-shape bottle, ethanol and isopropyl alcohol are removed in 46 ℃ of water-bath decompressions, on the bottle wall, form uniformly transparent film;
(3) in eggplant-shape bottle, adding the 400ml pH value is 7.0 phosphate buffered solution, continues to make the films swell hydration 46 ℃ of water-bath normal pressures rotations;
(4) with above-mentioned solution with 0.45 μ m filtering with microporous membrane, filtrating is placed-20 ℃ of refrigerator and cooled freeze and spends the night, take out to melt then, multigelation three times, spray drying makes paroxetine hydrochloride liposome powder;
(5) paroxetine hydrochloride lipidosome solid powder and 12g sorbitol, 6g pregelatinized Starch, 4g low-substituted hydroxypropyl cellulose and 4g ethyl cellulose are mixed, the mix homogeneously that sieves adds 30% an amount of alcoholic solution and prepares soft material, the preparation that sieves, drying;
(6) with dried granule and 2g Pulvis Talci mix homogeneously, granulate sieves;
(7) tabletting makes 1000 paroxetine hydrochloride liposome sheets.
Embodiment 2 paroxetine hydrochloride liposome sheets
Used supplementary material is following:
Adopt following production technology to prepare paroxetine hydrochloride liposome sheet:
(1) accurately takes by weighing 20g paroxetine hydrochloride, 20g hydrogenated yolk lecithin, 6g cholesterol, 15g hydrogenated soya phosphatide, 14g polysorbate40,18g PEG600, add the 400ml volume ratio and be 3: 1 ethanol and isopropyl alcohol mixed solvent, stir and make its dissolving;
(2) above-mentioned solution is placed eggplant-shape bottle, ethanol and isopropyl alcohol are removed in 46 ℃ of water-bath decompressions, on the bottle wall, form uniformly transparent film;
(3) in eggplant-shape bottle, add 400ml pH value 7.0 salt buffer solutions, continue to make the films swell hydration 46 ℃ of water-bath normal pressure rotations;
(4) with above-mentioned solution with 0.45 μ m filtering with microporous membrane, filtrating is placed-20 ℃ of refrigerator and cooled freeze and spends the night, take out to melt then, multigelation three times, spray drying makes paroxetine hydrochloride liposome powder;
(5) paroxetine hydrochloride lipidosome solid powder and 8g sorbitol, 6g pregelatinized Starch, 4g low-substituted hydroxypropyl cellulose and 4g ethyl cellulose are mixed, the mix homogeneously that sieves adds 30% an amount of alcoholic solution and prepares soft material, the preparation that sieves, drying;
(6) with dried granule and 2g Pulvis Talci mix homogeneously, granulate sieves;
(7) tabletting makes 1000 paroxetine hydrochloride liposome sheets.
Embodiment 3 paroxetine hydrochloride liposome sheets
Used supplementary material is following:
Adopt following production technology to prepare paroxetine hydrochloride liposome sheet:
(1) accurately take by weighing 20g paroxetine hydrochloride, 50g hydrogenated yolk lecithin, 16g cholesterol, 34g hydrogenated soya phosphatide, 18g polysorbate40,30g PEG600, adding 400ml volume ratio is 3: 1 ethanol and an isopropyl alcohol mixed solvent, stirs and makes its dissolving;
(2) above-mentioned solution is placed eggplant-shape bottle, ethanol and isopropyl alcohol are removed in 46 ℃ of water-bath decompressions, on the bottle wall, form uniformly transparent film;
(3) in eggplant-shape bottle, adding the 400ml pH value is 7.0 phosphate buffered solution, continues to make the films swell hydration 46 ℃ of water-bath normal pressures rotations;
(4) with above-mentioned solution with 0.45 μ m filtering with microporous membrane, filtrating is placed-20 ℃ of refrigerator and cooled freeze and spends the night, take out to melt then, multigelation three times, spray drying makes paroxetine hydrochloride liposome powder;
(5) paroxetine hydrochloride lipidosome solid powder and 12g sorbitol, 6g pregelatinized Starch, 4g low-substituted hydroxypropyl cellulose and 4g ethyl cellulose are mixed, the mix homogeneously that sieves adds 30% an amount of alcoholic solution and prepares soft material, the preparation that sieves, drying;
(6) with dried granule and 2g Pulvis Talci mix homogeneously, granulate sieves;
(7) tabletting makes 1000 paroxetine hydrochloride liposome sheets.
Comparative Examples 1-4
Adopt with embodiment 1-3 in step (1)～(4) prepare the identical production technology of paroxetine hydrochloride liposome powder, the supplementary material composition in will the Comparative Examples 1-4 shown in following table 1 is processed paroxetine hydrochloride liposome powder respectively:
Raw materials used composition among the table 1 Comparative Examples 1-4
Wherein, "/" expression is not used.
The mensuration of Test Example 1 envelop rate
To carrying out quality investigation respectively with the paroxetine hydrochloride liposome powder of Comparative Examples 1-4 gained in the embodiment 1-3 step (4), mainly carry out liposome morphologic observation, particle size determination and liposome encapsulation and measure.
Wherein, liposome form and particle size determination adopt optical microscopy and the computing of statistica5.0 statistical software to observe about 2000 to average;
Entrapment efficiency determination is the conventional mensuration of liposome, adopts ultrafiltration to measure the envelop rate of paroxetine hydrochloride liposome.In brief, utilize ultrafiltration to isolate free drug; Utilize methanol to destroy liposome, carry out assay with HPLC method and standard control then, calculate entrapment efficiency according to the envelop rate formula to extract medicine.
The result is shown in the following table 2:
The mensuration result of table 2 envelop rate
Can know that by table 2 compare with the liposome in the comparative example, the envelop rate of paroxetine hydrochloride liposome of the present invention will exceed a lot.
Can know that through comparing embodiment 1-3 and Comparative Examples 1-4 liposome of the present invention has higher envelop rate.The envelop rate of paroxetine hydrochloride liposome is relevant with the composition that is used to form liposome.Especially, when the composition beyond the used composition of use the present invention, the envelop rate of gained paroxetine hydrochloride liposome is starkly lower than the present invention.
Can know that through comparing embodiment 1-3 and Comparative Examples 1-4 (especially 3) envelop rate of paroxetine hydrochloride liposome is not only relevant with the composition that is used to form liposome, also directly related with the consumption of each composition.When the composition consumption was outside the composition amount ranges that the present invention limits, the envelop rate of gained paroxetine hydrochloride liposome was starkly lower than the present invention.
Percolation ratio is by formula Q
Ooze%=(W
Bag-W
Storage)/W
Bag* 100% calculates percolation ratio.The sample percolation ratio of inventive embodiments 1-3 preparation is very low, and less than 3% or almost there is not the seepage phenomenon, and the sample permeability of Comparative Examples 1-4 preparation increases gradually, and percolation ratio can reach 30%.
The size and the particle size distribution of Test Example 2 liposome particle diameters
In order to understand paroxetine hydrochloride liposome particle size parameters and particle size distribution accurately; Be taken at an amount of liposome powder of gained in the step (4) among embodiment 1-3 and the Comparative Examples 1-4; Directly with laser particle size analyzer (Easysizer20; America and Europe's gram company) observes its outer light; And mensuration particle diameter; Handle with the dynamic light scattering process software, the distribution of measuring its diameter and calculating particle diameter, the result is shown in the following table 3:
Table 3 liposome particle diameter
Can be known that by table 3 mean diameter of gained liposome is little more a lot of than the mean diameter of gained liposome among the Comparative Examples 1-4 among the embodiment of the invention 1-3, and the size homogeneous, outward appearance is better.
Can know that through comparing embodiment and Comparative Examples liposome of the present invention has littler mean diameter, particle size distribution is more even, and outward appearance is better.This shows that the particle diameter of paroxetine hydrochloride liposome is directly related with the composition kind that is used to form liposome.When the composition beyond the used composition of use the present invention, the character such as mean diameter, particle size distribution and outward appearance of gained paroxetine hydrochloride liposome obviously are inferior to the present invention.
Can know that through comparing embodiment 1-3 and Comparative Examples 1-4 liposome of the present invention has littler mean diameter, particle size distribution is more even, and outward appearance is better.This shows that the particle diameter of paroxetine hydrochloride liposome is not only relevant with the composition that is used to form liposome, and is also directly related with the consumption of each composition.When the composition consumption was outside the composition amount ranges that the present invention limits, the character such as mean diameter, particle size distribution and outward appearance of gained paroxetine hydrochloride liposome obviously were inferior to the present invention.
Existing research shows; Liposome particles size and the degree of being evenly distributed and its envelop rate and stability and relevant in the intravital time of staying of people; Liposome particles is more little, particle size distribution is even more; Its envelop rate and stability are high more, the time of staying in the human recycle system longer (referring to novel pharmaceutical formulation, front page; The 18 chapter; The 408-468 page or leaf, Zhu Shengshan chief editor, Chemical Industry Press).The document is introduced here as a reference in full.
Therefore, little, the particle size distribution of paroxetine hydrochloride liposome mean diameter of the present invention evenly is a factor that further promotes excellent performances such as its envelop rate, stability, retention time time length in vivo, bioavailability.
Test Example 3 stability and dissolution are investigated
40 ℃ of high temperature, following 6 months of relative humidity 75% ± 5% condition is carried out the accelerated test investigation with the paroxetine hydrochloride sheet (Sino-America Tianjin Shike Pharmaceutical Co., Ltd.'s lot number 20100701) of the sample of above embodiment 1-3 preparation and listing, and the result sees table 4.
Table 4 stability and dissolution determination result
Can be known that by table 4 the paroxetine hydrochloride sheet dissolution of listing is low, content reduces obviously when quickening June, and related substance raises; And the sample dissolution of preparation is high in the embodiment of the invention 1 and 3, quickens that content and related substance all do not have significant change after 6 months.Proved absolutely the present invention at the superiority that improves aspect stability and the dissolution, obtained can't rational expectation beyond thought effect.
Test Example 4 release in vitro researchs
Precision takes by weighing the paroxetine hydrochloride sheet (Sino-America Tianjin Shike Pharmaceutical Co., Ltd.'s lot number 20100701) of listing and each 1g of sample (amount with paroxetine hydrochloride is as the criterion) of embodiment 1-3 is dissolved in the 10ml water; Accurate each 2ml of suspension that draws places bag filter to tighten; Be fixed on the stirring paddle of digestion instrument; Release medium is phosphate buffered solution (containing 0.25% the polysorbas20) 100ml of pH 6.8; Bath temperature is 37 ℃; Speed of agitator is 100rpm; Respectively at 0.5; 1; 2; 4; 6; 8; 12; 18; The 24h 1ml that takes a sample; Measure release rate; Draw release profiles, shown in result such as the accompanying drawing 1.Wherein, the correlated paroxetine hydrochloride sheet of curve 1 expression listing, the sample of curve 2 expression embodiment 1, the sample of curve 3 expression embodiment 2, the sample of curve 4 expression embodiment 3.
The result shows that paroxetine hydrochloride listing medicine rate of release is very fast, and the release of gained paroxetine hydrochloride lipidosome solid preparation is slow among the embodiment of the invention 1-3, has reached the effect of slow release.
Industrial applicibility
Result by the foregoing description and Test Example can know; Paroxetine hydrochloride lipidosome solid preparation of the present invention has good surface appearance; Granule is little, and particle diameter is even, and envelop rate is high; Stability is high; Stripping property is good, and percolation ratio is low, and the time of staying in vivo is long; Bioavailability is high, has the favorable industrial using value.
More than describe the present invention; But should understand; These explanations do not constitute any restriction to scope of the present invention; Under the situation that does not depart from spirit of the present invention and protection domain; We carry out multiple modification, improvement and replacement to technical scheme of the present invention and embodiment thereof, and these all are in protection scope of the present invention.
The list of references of mentioning in the application of quoting, at this in full for reference only.
Claims (10)
1. paroxetine hydrochloride liposome, it is processed by the supplementary material composition that comprises following weight proportion:
Condition is: hydrogenated yolk lecithin: cholesterol: the weight ratio of hydrogenated soya phosphatide is 3～4: 1: 2～3; Hydrogenated yolk lecithin preferably: cholesterol: the weight ratio of hydrogenated soya phosphatide is 3: 1: 2.
2. paroxetine hydrochloride liposome according to claim 1, it is preferably the supplementary material composition that comprises following weight proportion and processes:
3. the method for preparing of the arbitrary said paroxetine hydrochloride liposome of claim 1-2, this method may further comprise the steps:
(a) paroxetine hydrochloride, hydrogenated yolk lecithin, cholesterol, hydrogenated soya phosphatide, polysorbate40 and PEG600 are dissolved in the organic solvent, stir and make its dissolving;
(b) above-mentioned solution is placed eggplant-shape bottle, organic solvent is removed in 46 ℃ of water-bath decompressions, on the bottle wall, forms uniformly transparent film;
(c) in eggplant-shape bottle, add buffer solution, continue to make the films swell hydration 46 ℃ of water-bath normal pressure rotations;
(d) with above-mentioned solution with 0.45 μ m filtering with microporous membrane, filtrating is placed-20 ℃ of refrigerator multigelations three times, spray drying makes paroxetine hydrochloride liposome powder.
4. method according to claim 3; Wherein, Organic solvent described in the step (a) is selected from one or more in ethanol, chloroform, dichloromethane, methanol, n-butyl alcohol, isopropyl alcohol, acetone, benzyl alcohol, the tert-butyl alcohol, the normal hexane, and preferred volume ratio is 3: 1 the ethanol and the mixed solvent of isopropyl alcohol;
Buffer salt solution described in the step (c) is selected from a kind of in phosphate buffer, citrate buffer, acetate buffer, borate buffer solution and the carbonate buffer solution, and preferred pH value is 7.0 phosphate buffered solution.
5. paroxetine hydrochloride lipidosome solid preparation, it is processed by the arbitrary described paroxetine hydrochloride liposome of claim 1-2 and other pharmaceutic adjuvants.
6. paroxetine hydrochloride lipidosome solid preparation according to claim 5, wherein based on the paroxetine hydrochloride of 1 weight portion, the amount of other pharmaceutic adjuvants is 1-3.5 part.
7. according to the arbitrary described lipidosome solid preparation of claim 5-6, it is a tablet.
8. method for preparing according to the arbitrary said paroxetine hydrochloride lipidosome solid preparation of claim 5-6, this method may further comprise the steps:
(1) preparation of paroxetine hydrochloride liposome: paroxetine hydrochloride, hydrogenated yolk lecithin, cholesterol, hydrogenated soya phosphatide, polysorbate40 and PEG600 are prepared into the liposome powder together;
(2) preparation of paroxetine hydrochloride lipidosome solid preparation: liposome powder and other pharmaceutic adjuvants are mixed with the paroxetine hydrochloride lipidosome solid preparation.
9. method according to claim 8, wherein the preparation of step (1) paroxetine hydrochloride liposome comprises following substep:
(a) paroxetine hydrochloride, hydrogenated yolk lecithin, cholesterol, hydrogenated soya phosphatide, polysorbate40 and PEG600 are dissolved in the organic solvent, stir and make its dissolving;
(b) above-mentioned solution is placed eggplant-shape bottle, organic solvent is removed in 46 ℃ of water-bath decompressions, on the bottle wall, forms uniformly transparent film;
(c) in eggplant-shape bottle, add buffer solution, continue to make the films swell hydration 46 ℃ of water-bath normal pressure rotations;
(d) with above-mentioned solution with 0.45 μ m filtering with microporous membrane, filtrating is placed-20 ℃ of refrigerator multigelations three times, spray drying makes paroxetine hydrochloride liposome powder;
Wherein, Organic solvent described in the substep (a) is selected from one or more in ethanol, chloroform, dichloromethane, methanol, n-butyl alcohol, isopropyl alcohol, acetone, benzyl alcohol, the tert-butyl alcohol, the normal hexane, and preferred volume ratio is 3: 1 ethanol and an isopropyl alcohol mixed solvent;
Buffer salt solution described in the substep (c) is selected from a kind of in phosphate buffer, citrate buffer, acetate buffer, borate buffer solution and the carbonate buffer solution, and preferred pH value is 7.0 phosphate buffered solution.
10. method according to claim 8, wherein, the preparation of step (2) paroxetine hydrochloride liposome solid preparation comprises following substep:
(e) paroxetine hydrochloride liposome powder and diluent, disintegrating agent and binding agent are mixed, the mix homogeneously that sieves adds wetting agent and prepares soft material, the granulation of sieving, and drying must be done granule.
(g) tabletting makes the paroxetine hydrochloride lipidosome solid preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102719701A CN102302453B (en) | 2011-09-14 | 2011-09-14 | Paroxetine hydrochloride liposome solid preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102719701A CN102302453B (en) | 2011-09-14 | 2011-09-14 | Paroxetine hydrochloride liposome solid preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102302453A true CN102302453A (en) | 2012-01-04 |
| CN102302453B CN102302453B (en) | 2012-11-21 |
Family
ID=45376443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011102719701A Expired - Fee Related CN102302453B (en) | 2011-09-14 | 2011-09-14 | Paroxetine hydrochloride liposome solid preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102302453B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE20190084A3 (en) * | 2017-05-30 | 2023-07-19 | Glaxosmithkline Biologicals Sa | Novel methods for manufacturing an adjuvant |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004091578A2 (en) * | 2003-04-09 | 2004-10-28 | Biodelivery Sciences International, Inc. | Novel encochleation methods, cochleates and methods of use |
| CN1568987A (en) * | 2004-05-13 | 2005-01-26 | 南昌弘益科技有限公司 | Dripping pills of paroxetine hydrochloride and its preparation method |
| WO2005063213A1 (en) * | 2003-12-19 | 2005-07-14 | Biodelivery Sciences International, Inc. | Rigid liposomal cochleate and methods of use and manufacture |
| CN1853631A (en) * | 2005-04-27 | 2006-11-01 | 上海秀新臣邦医药科技有限公司 | Fast disintegrant containing paroxetine |
| CN101143136A (en) * | 2006-09-13 | 2008-03-19 | 广东中大南海海洋生物技术工程中心有限公司 | Paroxetine slow release micropills preparation |
| CN101371836A (en) * | 2007-08-23 | 2009-02-25 | 珠海天翼医药技术开发有限公司 | Paroxetine enteric sustained-release composition |
| US20110142914A1 (en) * | 2007-12-06 | 2011-06-16 | Cytotech Labs, Llc | Inhalable compositions having enhanced bioavailability |
-
2011
- 2011-09-14 CN CN2011102719701A patent/CN102302453B/en not_active Expired - Fee Related
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004091578A2 (en) * | 2003-04-09 | 2004-10-28 | Biodelivery Sciences International, Inc. | Novel encochleation methods, cochleates and methods of use |
| WO2005063213A1 (en) * | 2003-12-19 | 2005-07-14 | Biodelivery Sciences International, Inc. | Rigid liposomal cochleate and methods of use and manufacture |
| CN1568987A (en) * | 2004-05-13 | 2005-01-26 | 南昌弘益科技有限公司 | Dripping pills of paroxetine hydrochloride and its preparation method |
| CN1853631A (en) * | 2005-04-27 | 2006-11-01 | 上海秀新臣邦医药科技有限公司 | Fast disintegrant containing paroxetine |
| CN101143136A (en) * | 2006-09-13 | 2008-03-19 | 广东中大南海海洋生物技术工程中心有限公司 | Paroxetine slow release micropills preparation |
| CN101371836A (en) * | 2007-08-23 | 2009-02-25 | 珠海天翼医药技术开发有限公司 | Paroxetine enteric sustained-release composition |
| US20110142914A1 (en) * | 2007-12-06 | 2011-06-16 | Cytotech Labs, Llc | Inhalable compositions having enhanced bioavailability |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE20190084A3 (en) * | 2017-05-30 | 2023-07-19 | Glaxosmithkline Biologicals Sa | Novel methods for manufacturing an adjuvant |
| US12016919B2 (en) | 2017-05-30 | 2024-06-25 | Glaxosmithkline Biologicals Sa | Methods for manufacturing an adjuvant |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102302453B (en) | 2012-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK284950B6 (en) | Process for the preparation of galenic forms of fenofibrate and their use | |
| CN102579350A (en) | Pidotimod liposome solid preparation | |
| MX2009002336A (en) | Imatinib compositions. | |
| EP2374450A1 (en) | Flupentixol compositions | |
| EP2050436A1 (en) | Pharmaceutical composition containing dutasteride | |
| CN102406606A (en) | Quetiapine fumarate liposome solid preparation | |
| CN102614182B (en) | Solid preparation of compound ammonia phenol renin medicine composition liposome | |
| CN102302453B (en) | Paroxetine hydrochloride liposome solid preparation | |
| CN101862336B (en) | Irbesartan-hydrochlorothiazide drug combination liposome solid preparation | |
| CN107206011A (en) | Complex capsule including Raloxifene and vitamin D or derivatives thereof | |
| CN102579345B (en) | Irbesartan liposome solid preparation | |
| CN102028658B (en) | Solid preparation containing rosuvastain calcium liposome | |
| CN102716098A (en) | Cefditoren pivoxil liposome solid preparation | |
| RU2674978C2 (en) | Pharmaceutical composition of n-[5-[2-(3,5-dimethoxyphenyl) ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl] benzamide | |
| CN101642433B (en) | Nimesulide liposome solid preparation and preparation method of drug composite thereof | |
| CN102078300B (en) | Solid preparation of Torasemide liposome | |
| CN103040777B (en) | Olmesartan ester liposome solid preparation | |
| CN102579344B (en) | Losartan potassium liposome solid preparation | |
| CN102266289B (en) | Cilnidipine liposome solid preparation | |
| CN102626388B (en) | Liposome solid preparation of ozagrel | |
| CN101829071B (en) | Aliskiren liposome tablet | |
| CN101862329A (en) | Amlodipine besylate and atorvastatin calcium medicine compound liposome solid preparation | |
| CN102626391B (en) | Aliskiren-hydrochlorothiazide drug combination liposome solid preparation | |
| CN102716084B (en) | Fluoxetine hydrochloride liposome solid preparation | |
| CN102626395B (en) | Solid preparation of aliskiren-valsartan pharmaceutical composition liposome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121121 Termination date: 20160914 |